GI-Y1

GI-Y1: sourced facts only. name: "Collectively, these findings indicate that GI-Y1 exerts protective effects on sepsis-related cardiac dysfunction by targeting GSDMD and inhibiting its mediated pyroptosis." [PMID:40716636]; target: "Collectively, these findings indicate that GI-Y1 exerts protective effects on sepsis-related cardiac dysfunction by targeting GSDMD and inhibiting its mediated pyroptosis." [PMID:40716636]; developer: "Department of Geriatric Medicine, The First Affiliated Hospital of Wenzhou Medical University, Zhejiang, People's Republic of China; The First Clinical Medical College, Wenzhou Medical University, Zhejiang, People's Republic of China." [PMID:40716636]; modality: "The GSDMD inhibitor Y1 (GI-Y1), a new small-molecule inhibitor developed through structure-based virtual screening against the GSDMD-N terminal domain, demonstrates selective binding affinity and potent inhibitory activity as shown in preliminary screening assays." [PMID:40716636]; stage: "Our systematic evaluation revealed that GI-Y1 significantly improved cardiac function and reduced myocardial injury in septic mice induced by lipopolysaccharide (LPS) and cecal ligation and puncture (CLP)." [PMID:40716636]